Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer

Anti-Cancer Drug Design

Volumn 15, Issue 1, 2000, Pages 3-16

  Fry, David W ^a  

^a PFIZER INC   (United States)

Author keywords

Cancer; Chemotherapy; EGF; erbB2; Phosphorylation; Tyrosine kinase inhibitor

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR;

CANCER; CANCER CHEMOTHERAPY; DRUG TARGETING; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUBSTRATE SPECIFICITY;

EID: 0034043977     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (150)

1. Aaronson S.A. (1991) Growth factors and cancer. Science, 254, 1146.
2. Bacus S.S., Zelnick C.R., Plowman G., Yarden Y. (1994) Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers-implication for tumor biology and clinical behavior. American Journal of Clinical Pathology, 102, S13.
3. Baker B.R. (1967) Design of Active-site Directed Irreversible Enzyme Inhibitors: the Organic Chemistry of the Enzyme Active-site. Wiley: New York.
4. Bartlett J.M., Langdon S.P., Simpson B.J., Stewart M., Datsaros D., Sismondi P., Love S., Scott W.N., Williams A.R., Lessells A.M., Macleod K.G., Smyth J.F., Miller W.R. (1996) The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. British Journal of Cancer, 73, 301.
5. Ben-Levy R., Paterson H. F., Marshall C.J., Yarden Y. (1994) A single autophosphorylation site confers oncogenicity to the neu/erbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO Journal, 13, 3302.
6. Bridges A.J. (1995) The current status of tyrosine kinase inhibitors: do the diarylamine inhibitors of the EGF receptor represent a new beginning? Expert Opinions in Therapeutic Patents, 5, 1245.
7. Bridges A.J. (1999a) Irreversible inhibitors of tyrosine kinases. World patent application, WO 9906378.
8. Bridges A.J. (1999b) The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Current Medicinal Chemistry, 6, 825.
9. Bridges A.J., Cody D.R., Zhou H., McMichael A., Fry D.W. (1995) Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(a-phenethylamino)-quinazolines. Bioorganic Medicinal Medicine, 3, 1651.
10. Bridges A.J., Zhou H., Cody D.R., Rewcastle G.W., McMichael A., Showalter H. D.H., Fry D.W., Kraker A.J., Denny W.A. (1996) Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. Journal of Medicinal Chemistry, 39, 267.
11. Bridges A.J., Denny W.A., Dobrusin E.M., Doherty A.M., Fry D.W., McNamara D.J., Showalter H.D.H., Smaill J.B., Zhou H. (1997) Irreversible inhibitors of tyrosine kinases. World patent application, WO 9738983.
12. Brunton V.G., Workman P. (1993) Cell-signaling targets for antitumour drug development. Cancer Chemotherapy and Pharmacology, 32, 1.
13. Bucci B., D'Agnano I., Botti C., Mottolese M., Carico E., Zupi G., Vecchione A. (1997) EGF-R expression in ductal breast cancer: proliferation and prognostic implications. Anticancer Research. 17, 769.
14. Buhrow S.A., Cohen S., Staros J.V. (1982) Affinity labeling of the protein kinase associated with the epidermal growth factor receptor in membrane vesicles from A431 cells. Journal Biological Chemistry, 257, 4019.
15. Buhrow S.A., Cohen S., Garbers D.L., Staros J.V. (1983) Characterization of the interaction of 5′-p-fluorosulfonyl-benzoyl adenosine with the epidermal growth factor receptor/protein kinase in A431 cell membranes. Journal of Biological Chemistry, 258, 7824.
16. Burke C.L., Lemmon M.A., Coren B.A., Engelman D.M., Stern D.F. (1997) Dimeriza:ion of the p185(neu) transmembrane domain is necessary but not sufficient for transformation. Oncogene, 14, 687.
17. Burke T.R. (1992) Protein-tyrosine kinase inhibitors. Drugs of the Future, 17, 119-131.
18. Cadena D.L., Gill G.N. (1992) Receptor tyrosine kinases. FASEB Journal, 6, 2332.
19. Cantley L.C., Auger K.R., Carpenter C., Duckworth B., Graziani A., Kapeller R., Soltoff S. (1991) Oncogenes and signal transduction. Cell, 64, 281.
20. Carraway K.L. III (1996) Involvement of the neuregulins and their receptors in cardiac and neural development. Bioessays, 18, 263.
21. Carraway K.L., Cantley L.C. (1994) A neu acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerization in growth signaling. Cell, 78, 5.
22. Carraway K.L., Weber J.L., Unger M.J., Ledesma J., Yu N., Gassmann M., Lai C. (1997) Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature, 387, 512.
23. Chang H., Riese D.J., Gilbert W, Stern D.F, McMahan U.J. (1997) Ligands for ErbB-family receptors encoded by a newly characterized neuregulin-like gene. Nature, 387, 509.
24. Chiao P.J., Bischoff F.Z., Strong L.C., Tainsky M.A. (1990) The current state of oncogenes and cancer: experimental approaches for analyzing oncogenetic events in human cancer. Cancer and Metastases Reviews, 9, 63.
25. Clark S., Konstantopoulos N. (1993) Sulphydryl agents modulate insulin- and epidermal growth factor (EGF)-receptor kinase via reaction with intracellular receptor domains: differential effects on basal versus activated receptors. Biochemical Journal, 292, 217.
26. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl R.S., Fehrenbacher L., Paton V, Shak S., Lieberman G., Slamon D. (1998) Efficacy and safetly of herceptin™ (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proceedings of the American Society of Clinical Oncology, 17, 97a.
27. Colman R.F. (1983) Affinity labeling of purine nucleotide sites in proteins. Annual Review of Biochemistry, 52, 67.
28. Colman R.F., Bailey J.M., DeCamp D.L., Huang Y-C., Vollmer S.H. (1990) Affinity labeling of adenine nucleotide sites in enzymes. Annuals of the New York Academy of Sciences, 603, 417.
29. Daly R.J. (1999) Take your partners, please-signal diversification by the erbB family of receptor tyrosine kinases. Growth Factors, 16, 255.
30. Dankort D.L., Wang Z., Blackmore V., Moran M.F., Muller W.J. (1997) Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Molecular and Cellular Biology, 17, 5410.
31. Davies D.E., Chamberlin S.G. (1996) Targeting the epidermal growth factor receptor for therapy of carcinomas. Biochemical Pharmacology, 51, 1101.
32. Decker S.J. (1984) Aspects of the metabolism of the epidermal growth factor receptor in A431 human epidermoid carcinoma cells. Molecular and Cellular Biology, 4, 571.
33. Denhardt D.T. (1996) Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. Biochemical Journal, 318, 729.
34. Denny W.A., Rewcastle G.W., Bridges A.J., Fry D.W., Kraker A.J. (1996) Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro. Clinical and Experimental Pharmacology and Physiology, 23, 424.
35. Denny W.A., Palmer B.D., Rewcastle G. W., Thompson A.M., Bridges A.J., Doherty A.M., Fry D.W., Nelson J.M., Rubin J.R., Showalter H.D.H., Trumpp-Kallmeyer S. (1997) Pyrido[d]pyrimidine inhibitors of the tyrosine kinase activity of the EGF receptor: a binding model and structure-activity relationships for soluble analogues. Proceedings of the American Association of Cancel-Research, 38, 633.
36. Depotter C.R. (1994) The neu-oncogene: more than a prognostic indicator? Human Pathology, 25, 1264.
37. Discafani C.M., Carroll M.L., Floyd M.B. Jr, Hollander I.J., Husain Z., Johnson B.D., Kitchen D., May M.K., Malo M.S., Minnick A.A. Jr, Nilakantan R., Shen R., Wang Y-F., Wissner A., Greenberger L.M. (1999) Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)-amino]-6-quinazolinyl]-2-butynamide (CL-387,785). Biochemical Pharmacology, 57, 917.
38. Dougall W.C., Qian X., Greene M.I. (1993) Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy. Journal of Cellular Biochemistry, 53, 61.
39. Elliott W.L., Fry D.W., Vincent P.W., Roberts B.J., Howard C.T., Slintak V., Nelson J.M., Hook K.E., Showalter H.D.H., Winters T.R., Denny W.A., Thompson A.M. (1997) In vitro and in vivo activity of 4-anilinopyrido-pyridimine EGF family specific tyrosine kinase inhibitors. Proceedings of the American Association of Cancer Research, 38, 470.
40. Fazioli F., Kim U.-H, Rhee S.O., Molloy C.J., Segatto O., DiFiore P.P. (1991) The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phopholipase C-γ and GTPase-activating protein does not correlate with erbB-2 mitogenic potency. Molecular and Cellular Biology, 11, 2040.
41. Fiddes R.J., Janes P.W., Sanderson G.M., Sivertsen S.P., Sutherland R.L., Daly R.J. (1995) Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells. Cell Growth and Differentiation, 6, 1567.
42. Fiddes R.J., Campbell D.H., Janes P.W., Sivertsen S.P., Sasaki H., Wallasch C., Daly R.J. (1998) Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3. Journal of Biological Chemistry, 273, 7717.
43. Fischbach G.D., Rosen K.M. (1997) ARIA: a neuromuscular junction neuregulin. Annual Reviews in Neuroscience, 20, 429.
44. Fry D.W. (1994) Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors. Expert Opinions in Investigational Drugs, 3, 577.
45. Fry D.W. (1996) Recent advances in tyrosine kinase inhibitors. Annual Reports in Medicinal Chemistry, 31, 151.
46. Fry D.W. (1999) Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacology and Therapeutics, 82, 207.
47. Fry D.W., Bridges A.J. (1995) Inhibitors of protein tyrosine kinases. Current Opinions in Biotechnology, 6, 662.
48. Fry D.W., Kraker A.J., McMichael A., Ambroso L.A., Nelson J.M., Leopold W.R., Connors R.W., Bridges A.J. (1994) Specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science, 265, 1093.
49. Fry D.W., Nelson J.M., Slintak V., Keller P.R., Rewcastle G.W., Denny W.A., Zhou H.R., Bridges A.J. (1997) Biochemical and antiproliferative properties of 4-[ar-(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochemical Pharmacology, 54, 877.
50. Fry D.W., Bridges A.J., Denny W.A., Doherty A., Greis K., Hicks J.L., Hook K.E., Keller P.R., Leopold W.R., Loo J., McNamara D.J., Nelson J.M., Sherwood V., Smaill J.B., Trumpp-Kallmeyer S., Dobrusin E.M. (1998) Specific, irreversible inactivation of the epidermal growth factor receptor and erbb2, by a unique class of tyrosine kinase inhibitor. Proceedings of the National Academy of Sciences. USA, 95, 12022.
51. Gazit A., Chen J., App H., McMahon G., Hirth P., Chen I., Levitzki A. (1996) Tyrphostins IV - highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines. Bioorganic and Medicinal Chemistry, 4, 1203.
52. Gibson K. (1996) Quinazoline derivatives. World patent application, WO 96/33980.
53. Gibson K.H., Grundy W., Godfrey A.A., Woodburn J.R., Ashton S.E., Curry B.J., Scarlett L., Barker A.J., Brown D.S. (1997) Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumour activity of novel quinazolines. Bioorganic Medicinal Chemistry Letters, 7, 2723.
54. Goldman R., Ben Levy R., Peles E., Yarden Y. (1990) Heterodimerization of the erbB1 and erbB2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry, 29, 11024.
55. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO Journal, 16, 1647.
56. Grasso A.W., Wen D., Miller C.M., Rhim J.S., Pretlow T.G., Kung H.-J. (1997) ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene, 15, 2705.
57. Hackel P.O., Zwick E., Prenzel N., Ullrich A. (1999) Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Current Opinion in Cell Biology, 11, 184.
58. Hammond L., Ranson M., Ferry D., Kris M., Kelly H., Ochs J., Averbuch S., Rowinsky E. (1999) AG 1839, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor: first phase 1, pharmacokinetic (PK) results in patients. Proceedings of the American Society of Clinical Oncology, 18, 388a.
59. 6-(6-idodoacetamido-n-hexyl)adenosine 5′-triphosphate. Journal of Medicinal Chemistry, 19, 1279.
60. Hampton A., Slotin L.A., Kappler F., Sasaki T., Perini F. (1976b) Design of substrate-site-directed inhibitors of adenylate kinase and hexokinase. Effect of substrate substituants on affinity for the adenine nucleotide sites. Journal of Medicinal Chemistry, 19, 1371.
61. Hanks S.K., Hunter T. (1995) Protein kinases 6 - the eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB Journal, 9, 576.
62. Harari D., Tzahar E., Romano J., Shelly M., Pierce J.H., Andrews G.C., Yarden Y. (1999) Neuregulin-4: a novel growth factor that acts through the erbB-4 receptor tyrosine kinase. Oncogene, 18, 2681.
63. Hunter T. (1991) Cooperation between oncogenes. Cell, 64, 249.
64. Hunter T. (1994) 1001 protein kinases reflux - towards 2000. Seminars in Cell Biology, 5, 367.
65. Hynes N.E., Stern D.F. (1994) The biology of erbB-2/neu/ HER-2 and its role in cancer. Biochimica et Biophysica Acta, 1198, 165.
66. Jallal B., Schlessinger J., Ullrich A. (1992) Tyrosine phosphalase inhibition permits analysis of signal transduction complexes in p185HER2/neu-overexpressing human tumor cells. Journal of Biological Chemistry, 267, 4357.
67. Janes P.W., Daly R.J., deFazio A., Sutherland R.L. (1994) Activation of the ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene, 9, 3601.
68. erbB2. Journal of Biological Chemistry, 268, 2924.
69. Jones J.T., Akita R.W., Sliwkowski M.X. (1999) Binding specificities and affinities of egf domains for ErbB receptors. FEBS Letters, 447, 227.
70. Kaplan D.R., Perkins A., Morrison D.K. (1993) Signal transduction by receptor tyrosine kinases. In Oncogenes and Tumor Suppressor Genes in Human Malignancies. Benz C.C., Liu E.T. (eds), p. 265. Kluwer Academic Publisher: Boston, MA.
71. Karp D.D., Silberman S.L., Csudae R., Wirth F., Gaynes L., Posner M., Bubley G., Koon H., Bergman M., Huang M., Schnipper L.E. (1999) Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients with advanced solid tumors. Proceedings of the American Society of Clinical Oncology, 18, 388a.
72. Khazaie K., Schirrmacher V., Lichtner R.B. (1993) EGF receptor in neoplasia and metastasis. Cancer and Metastases Reviews, 12, 255-274.
73. King C.R., Borrello I., Bellot G., Comoglio P., Schlessinger J. (1988) EGF binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. EMBO Journal, 7, 1647.
74. Klijn J.G.M., Berns P.M.J.J., Schmitz P.I. M., Foekens J.A. (1992) The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer - a review on 5232 patients. Endocrine Reviews, 13, 3.
75. Klijn J.G., Look M.P., Portengen H., Alexieva-Figusch J., van Putten W.L., Foekens J.A. (1994) The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Research and Treatment, 29, 73.
76. Klohs W.D., Fry D.W., Kraker A.J. (1997) Inhibitors of tyrosine kinase. Current Opinion in Oncology, 9, 562.
77. Komurasaki T., Toyoda H., Uchida D., Morimoto S. (1997) Epiregulin binds to epidermal growth factor receptor and erbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, erbB-2, erbB-3 and erbB-4. Oncogene, 15, 2841.
78. Kurganov B.I., Nagradova N.K., Lavrik O.I. (1996) Chemical Modification of Enzymes. Nova Science Publishers, Inc.: Commack, NY.
79. Laird A.D., Shalloway D. (1997) Oncoprotein signalling and mitosis. Cellular Signalling 9, 249.
80. Langdon S.P., Smyth J.F. (1995) Inhibition of cell signalling pathways. Cancer Treatment Reviews, 21, 65.
81. Lawrence D.S., Niu J.K. (1998) Protein kinase inhibitors: the tyrosine-specific protein kinases. Pharmacology and Therapeutics, 77, 81.
82. Levitzki A. (1992) Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB Journal, 6, 3275.
83. Levitzki A., Gazit A. (1995) Tyrosine kinase inhibition: an approach to drug development. Science, 267, 1782.
84. Levitzki A., Gilon C. (1991) Tyrphostins as molecular tools and potential antiproliferative drugs. Trends in Pharmacological Sciences, 12, 171.
85. Lutrell, d. K., Lee A., Lansing T.J., Crosby R.M., Jung K.D., Willard M., Rodriguez M., Berman J., Gilmer T.M. (1994) Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proceedings of the National Academy of Sciences, USA, 19, 83.
86. Marchionni M.A., Goodearl A.D.J., Chen M.S., Berminghan-McDonogh O., Kirk C., Hendricks M., Danehy F., Misumi D., Sudhalter J., Kobayashi K., Wroblewski D., Lynch C., Baldassare M., Hiles I., Davis J.B., Hsuan J.J., Totty N.F., Otsu M., McBurney R.N., Waterfield M.D., Stroobant P., Gwynne D. (1993) Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature, 362, 312.
87. Meden H., Marx D., Raab T., Schauer K.M., Kuhn W. (1995) EGF-R and overexpression of the Oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. Journal of Obstetrics and Gynaecology, 21, 167.
88. Meyer D., Birchmeier C. (1995) Multiple essential functions of neuregulin in development. Nature, 378, 386.
89. Moyer J.D., Barbacci E.G., Iwata K.K., Arnold L., Boman B., Cunningham A., DiOrio C., Doty J., Morin M.J., Moyer M.P., Neveu M., Pollack V.A., Pustilnik L.R., Reynolds M.M., Sloan D., Theleman A., Miller P. (1997) Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Research, 57, 4838.
90. Muller W.J., Arteaga C.L., Muthuswamy S.K., Siegel P.M., Webster M.A., Cardiff R.D., Meise K.S., Li F., Halter S.A., Coffey R.J. (1996) Synergistic interaction of the neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Molecular and Cellular Biology, 16, 5726.
91. Muthuswamy S.K., Siegel P.S., Dankort D.L., Webster M.A., Muller W.J. (1994) Mammary tumors expressing the new proto-Oncogene possess elevated c-src tyrosine kinase activity. Molecular and Cellular Biology, 14, 735.
92. Palfreyman M.G., McCann P.P., Lovenberg W., Temple J.G., Sjoerdsma A. (1989) Enzymes as Targets for Drug Design. Academic Press: San Diego, CA.
93. Palmer B.D., Trumpp-Kallmeyer S., Fry D.W., Nelson J.M., Showalter H.D.H., Denny W.A. (1997) Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, modeling of the mode of binding. Journal of Medicinal Chemistry, 40, 1519.
94. Patmore S.J., Roberts B.J., Stoner C.L., Vincent P.W., Leopold W.R., Dykes D.J., Denny W.A., Smaill J.B., Elliott W.L. (1998) In vivo evaluation of the irreversible EGF receptor tyrosine kinase inhibitor PD 168393. Proceedings of the American Association of Cancer Research, 39, 560.
95. Pawson T., Schlessinger J. (1993) SH2 and SH3 domains. Current Biology, 3, 434.
96. Pinkas-Kramarski R., Soussan L., Waterman H., Levkowitz G., Alroy I., Klapper L., Lavi S., Seger R., Ratzkin B.J., Sela M., Yarden Y. (1996) Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO Journal, 15, 2452.
97. Pollack V.A., Savage D.M., Baker D.A., Tsaparikos K.E., Sloan D.E., Barbacci E.G., Pustilnik L.R., Smolarek T.A., Davis J.A., Vaidya M.P., Iwata K. (1997) Therapy of human carcinomas in athymic mice by inhibition of EGF receptor-mediated signal transduction with CP-358774: Dynamics of receptor inhibition and anti-tumor effects. Proceedings of the American Association of Cancer Research, 38, 633.
98. Powis G. (1994) Signalling pathways as targets for anticancer drug development. Pharmacology and Therapeutics, 62, 57.
99. Qian X., Greene M.I. (1997) Her2/neu: a receptor tyrosine kinase with developmental and oncogenic activity. Encyclopedia of Cancer, 2: 835.
100. Qian X.L., Dougall W.C., Fei Z.Z., Greene M.I. (1995) Intermolecular association and rrans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation. Oncogene, 10, 211.
101. Rajkumar T., Gullick W.J. (1994) The type I growth factor receptors in human breast cancer. Breast Cancer Research and Treatment, 29, 3.
102. Ram T.G., Ethier S.P. (1996) Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Cell Growth and Differentiation, 7, 551.
103. Reese D.M., Slamon D.J. (1997) HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells, 15, 1.
104. Rewcastle G.W., Denny W.A., Bridges A.J., Zhou H.R., Cody D.R., McMichael A., Fry D.W. (1995) Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. Journal of Medicinal Chemistry, 38, 3482.
105. Rewcastle G.W., Palmer B.D., Bridges A.J., Showalter H. D.H., Li S., Nelson J., McMichael A., Kraker A.J., Fry D.W., Denny W.A. (1996a) Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. Journal of Medicinal Chemistry, 39, 918.
106. Rewcastle G.W., Palmer B.D., Thompson A.M., Bridges A.J., Cody D.R., Zhou H., Fry D.W., McMichael A., Denny WA. (1996b) Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. Journal of Medicinal Chemistry, 39, 1823.
107. Rewcastle G.W., Bridges A.J., Fry D.W., Rubin J.R., Denny W.A. (1997) Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido-[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor. Journal of Medicinal Chemistry, 40, 1820.
108. Riese D.J., Stern D.F. (1998) Specificity within the EGF family/erbB receptor family signaling network. Bioessays, 20, 41.
109. Riese D.J. II, Bermingham Y., van Raaij T.M., Buckely S., Plowman G.D., Stern D.F. (1996a) Betacellulin activates the epidermal growth factor receptor and erbB4, induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-β. Oncogens, 12, 345.
110. Riese D.J. II, Kim E.D., Elinius K., Buckely S., Klagsgrun M., Plowman G. D., Stern D.F. (1996b) The epidermal growth factor receptor couples transforming growth factor-α, heparin-binding epidermal growth factor-like factor, amphiregulin to neu, er3B3, erbB4. Journal Biological Chemistry, 271, 20047.
111. Russo M.W., Lukas T.J., Cohen S., Staros J.V. (1985) Identification of residues in the nucleotide binding site of the epidermal growth factor receptor kinase. Journal of Biological Chemistry, 260, 5205.
112. Salomon D.S., Brandt R., Ciardiello F., Normanno N. (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology and Hematology, 19, 183.
113. Scambia G., Benedetti-Panici P., Ferrandina G., Distefano M., Salerno G., Romanini M.E., Fagotti A., Mancuso S. (1995) Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. British Journal of Cancer, 72, 361.
114. Schlessinger J., Ullrich A. (1992) Growth factor signaling by receptor tyrosine kinases. Neuron, 9, 383.
115. Schnur R.C., Arnold L.D. (1996) Quinazoline derivatives. World patent application, WO 96/30347.
116. Scoggins R.M., Summerfield A.E., Stein R.A., Guyer C.A., Staros J.V. (1996) 5′-(p;-Fluorosulfonylbenzoyl)-2′(or 3′)-methylanthraniloyl)adenosine, fluorescent affinity labels for adenine nucleotide binding sites: interaction with the kinase active site of the receptor for epidermal growth factor. Biochemistry, 35, 9197.
117. Segatto O., Lonardo F., Helin K., Wexler D., Fazioli F., Rhee S.G., Di Fiore P.P. (1992) erbB-2 autophosphorylation is required for mitogenic action and high-affinity substrate coupling. Oncogene, 7, 1339.
118. Sepp-Lorenzino L., Eberhard I., Ma Z., Cho C., Serve H., Liu F., Rosen N., Lupu R. (1996) Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells. Oncogene, 12, 1679.
119. Shelly M., Pinkas-Kramarski R., Guarino B.C., Waterman H., Wang L.-M., Lyass L., Alimandi M., Kuo A., Bacus S.S., Pierce J.H., Andrews G. C., Yarden Y. (1998) Epiregulin is a potent pan-erbB ligand that preferentially activates heterodimeric receptor complexes. Journal of Biological Chemistry, 17, 10496.
120. Sherwood V., Bridges A.J., Denny W.A., Rewcastle G.W., Smaill J.B., Fry D.W. (1999) Selective inhibition of heregulin-dependent tyros:.ne phosphorylation and cellular signaling through erbB2, erbB3 and erbB4 by PD 158780 and a new irreversible inhibitor, PD 183805. Proceedings of the American Association for Cancer Research, 40, 723.
121. Singh J., Dobrusin E.M., Fry D.W., Haske T., Whitty A., McNamara D.J. (1997) Structure-based design of a potent, selective, irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. Journal of Medicinal Chemistry, 40, 1130.
122. Siu L.L., Hidalgo M., Nemunaitis J., Rizzo J., Moczygemba J., Eckhardt S.G., Tolcher A., Smith L., Hammond L., Blackburn A., Tensfeldt T., Silberman S., Von Hoff D.D., Rowinsky E.K. (1999) Dose and schedule-duration escalation of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774: a phase I and pharmacokinetic (PK) study. Proceedings of the American Society of Clinical Oncology, 18, 388a.
123. Smaill J.B., Palmer B.D., Rewcastle G.W., Denny W.A., McNamara D.J., Dobrusin E.M., Bridges A.J., Zhou H., Showalter H.D.H., Winters R.T., Leopold W.R., Fry D.W., Nelson J.M., Slintak V., Elliot W.L., Roberts B.J., Vincent P.W., Patmore S.J. (1999) Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido-[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. Journal of Medicinal Chemistry, 42, 1803.
124. Smaill J.B., Rewcastle G.W., Loo J.A., Greis K.D., Chan O.H., Reyner E.L., Lipka E., Showalter H.D.H., Fry D.W., Sherwood V., Nelson J.M., Denny WA. (2000) Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. Journal of Medicinal Chemistry, in press.
125. Songyang Z., Carraway K.L. III, Eck M.J., Harrison S.C., Feldman R.A., Mohammadi M., Schlessinger J., Hubbard S.R., Smith D.P., Eng C., Lorenzo M.J., Ponder B.A.J., Mayer B.J., Cantley L.C. (1995) Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature, 373, 536.
126. Spada A.P., Myers M.R. (1995) Small molecule inhibitors of tyrosine kinase activity. Opinions in Therapeutic Patents, 5, 805.
127. Stein D., Wu J., Fuqua S.A., Roonprapunt C., Yajnik V., D'Eustachio P., Moskow J.J., Buchberg A.M., Osborne C.K., Margolis B. (1994) The SH2 domain protein GRB7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO Journal, 13, 1331.
128. neu. A potential model for receptor interactions. EMBO Journal, 7, 1995.
129. Stern D.F., Heffernan P.A., Weinberg R.A. (1986) P185, a product of the neu proto-oncogene, is a receptor-like protein associated with tyrosine kinase activity. Molecular and Cellular Biology, 6, 1729.
130. Thompson A.M., Bridges A.J., Fry D.W., Kraker A.J., Denny W.A. (1995) Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]-pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. Journal of Medicinal Chemistry, 38, 3780.
131. Thompson A.M., Murray D.K., Elliott W.L., Fry D.W., Nelson J.A., Showalter H. D.H., Roberts B.J., Vincent P.W., Denny W.A. (1997) Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]-pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. Journal of Medicinal Chemistry, 40, 3915.
132. Toi M., Tominaga T., Osaki A., Toge T. (1994) Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical, study and an immunocytochemical study. Breast Cancer Research, 29, 51.
133. Toledo L.M., Lydon N.B., Elbaum D. (1999) The structure-based design of ATP-site directed protein kinase inhibitors. Current Medicinal Chemistry, 6, 775.
134. Traxler P. (1996) Pyrazole derivatives and processes for the preparation thereof. World patent application, WO96/ 31510.
135. Traxler P.M., Furet P., Mett H., Buchdunger E., Meyer T., Lydon N. (1996) 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. Journal of Medicinal Chemistry, 39, 2285.
136. Traxler P., Bold G., Frei J., Lang M., Lydon N., Mett H., Buchdunger E., Meyer T., Mueller M., Furet P. (1997) Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]-pyrimidines. Journal of Medicinal Chemistry, 40, 3601.
137. Tzahar E., Waterman H., Chen X.M., Levkowitz G., Karunagaran D., Lavi S., Ratzkin B.J., Yarden Y. (1996) A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Molecular and Cellular Biology, 16, 5276.
138. Tzahar E., Pinkas-Kramarski R., Moyer J.D., Kapper L.N., Alroy I., Levkowitz G., Shelly M., Henis S., Eisenstein M., Ratzkin B.J., Sela M., Andrews G.C., Yarden Y. (1997) Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO Journal, 16, 4938.
139. Ullrich A., Schlessinger J. (1990) Signal transduction by receptors with tyrosine kinase activity. Cell, 61, 203.
140. Vandergeer P., Hunter T., Lindberg R.A. (1994) Receptor protein-tyrosine kinases and their signal transduction pathways. Annual Review of Cellular Biology, 10, 251.
141. Vincent P.W., Akinson B.E., Zhou H., Dykes D., Leopold W.R., Patmore S.J., Roberts B.J., Bridges A., Elliott W.L. (1998) Characterization of the in vivo activity of a novel EGF receptor family kinase inhibitor, PD 168414. Proceedings of the American Association for Cancer Research, 39, 560.
142. Vincent P.W, Patmore S.J., Atkinson B.E., Bridges A.J., Kirkish L.S., Dudeck R.C., Leopold W.R., Zhou H., Elliott W.L. (1999) Optimal in vivo treatment schedule for the novel EGF receptor family tyrosine kinase inhibitor, PD 183805, correlates with the inhibition of receptor tyrosine phosphorylation. Proceedings of the American Association for Cancer Research, 39, 117.
143. Wada T., Qian X., Green M.I. (1990) Intermodular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell, 61, 339.
144. Ward W.H.J., Cook P.N., Slater A.M., Davies H., Holdgate G.A., Green L.R. (1994) Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochemical Pharmacology, 48, 659.
145. Ward N.E., Gravitt K.R., O'Brian C.A. (1995) Irreversible inactivation of protein kinase C by a peptide-substrate analog. Journal of Biological Chemistry, 270, 8056.
146. Wissner A., Johnson B.D., Middleton B., Floyd M.B., Kitchen D.B. (1998) 4-Aminoquinazoline EGFR inhibitors. United states patent application, US 5,760,041.
147. Woltjer R.L., Staros J.V. (1997) Effects of sulfhydryl modification reagents on the kinase activity of the epidermal growth factor receptor. Biochemistry, 36, 9911.
148. Woodburn J.R., Barker A.J., Gibson K.H., Ashton S.E., Wakeling A.E., Curry B.J., Scarlett L., Henthorn L.R. (1997) ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Proceedings of the American Association of Cancer Research, 38, 633.
149. Zhang D., Sliwkowski M.X., Mark M., Frantz G., Akita R., Sun Y., Hillan K., Crowley C., Brush J., Godowski P.J. (1997) Neuregulin-3 (NRG3): a novel
150. Zheng J., Knighton D.R., Ten Eyck L.F., Darlsson R., Xuong N., Taylor S.S., Sowadski J.M. (1993) Crystal structure of the catalytic subunit of the cAMP Ser/Thr-dependent protein kinase complexed with MgATP and peptide inhibitor. Biochemistry, 32, 2154.